CRP and irritable bowel syndrome: Hence, it’s important for clinicians to be aware of this limitation when using CRP as a biomarker in IBD, especially in UC, and to consider other markers, such as fecal calprotectin or endoscopic evaluation, when assessing disease activity [32,62].